Roth Capital Has Bullish Estimate for REVB FY2024 Earnings

Revelation Biosciences, Inc. (NASDAQ:REVB) – Roth Capital raised their FY2024 EPS estimates for Revelation Biosciences in a report issued on Wednesday, December 4th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of ($5.58) for the year, up from their prior estimate of ($6.22). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($7.48) per share. Roth Capital also issued estimates for Revelation Biosciences’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.00) EPS, FY2026 earnings at ($1.01) EPS and FY2027 earnings at ($0.96) EPS.

Revelation Biosciences Trading Up 2.3 %

Shares of REVB opened at $0.45 on Monday. Revelation Biosciences has a 12 month low of $0.42 and a 12 month high of $25.26. The firm’s 50 day moving average is $0.79 and its 200-day moving average is $1.25. The stock has a market capitalization of $1.93 million, a PE ratio of -0.03 and a beta of 0.15.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.